Pfizer/$PFE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Pfizer
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
Ticker
$PFE
Sector
Primary listing
NYSE
Employees
75,000
Headquarters
Website
Pfizer Metrics
BasicAdvanced
$153B
19.77
$1.36
0.41
$1.72
6.38%
Price and volume
Market cap
$153B
Beta
0.41
52-week high
$27.94
52-week low
$20.92
Average daily volume
42M
Dividend rate
$1.72
Financial strength
Current ratio
1.16
Quick ratio
0.796
Long term debt to equity
73.923
Total debt to equity
77.957
Dividend payout ratio (TTM)
125.74%
Interest coverage (TTM)
7.17%
Profitability
EBITDA (TTM)
25,689.332
Gross margin (TTM)
75.81%
Net profit margin (TTM)
12.42%
Operating margin (TTM)
30.62%
Effective tax rate (TTM)
-3.54%
Revenue per employee (TTM)
$830,000
Management effectiveness
Return on assets (TTM)
5.68%
Return on equity (TTM)
8.89%
Valuation
Price to earnings (TTM)
19.767
Price to revenue (TTM)
2.449
Price to book
1.77
Price to tangible book (TTM)
-5.55
Price to free cash flow (TTM)
16.889
Free cash flow yield (TTM)
5.92%
Free cash flow per share (TTM)
1.597
Dividend yield (TTM)
6.38%
Forward dividend yield
6.38%
Growth
Revenue change (TTM)
-1.65%
Earnings per share change (TTM)
-3.37%
3-year revenue growth (CAGR)
-14.80%
10-year revenue growth (CAGR)
2.51%
3-year earnings per share growth (CAGR)
-37.06%
10-year earnings per share growth (CAGR)
2.06%
3-year dividend per share growth (CAGR)
2.44%
10-year dividend per share growth (CAGR)
4.38%
What the Analysts think about Pfizer
Analyst ratings (Buy, Hold, Sell) for Pfizer stock.
Pfizer Financial Performance
Revenues and expenses
Pfizer Earnings Performance
Company profitability
Pfizer News
AllArticlesVideos
An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive
WSJ·4 hours ago
Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss
CNBC·7 hours ago
Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial
Market Watch·10 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Pfizer stock?
Pfizer (PFE) has a market cap of $153B as of March 23, 2026.
What is the P/E ratio for Pfizer stock?
The price to earnings (P/E) ratio for Pfizer (PFE) stock is 19.77 as of March 23, 2026.
Does Pfizer stock pay dividends?
Yes, the Pfizer (PFE) stock pays dividends to shareholders. As of March 23, 2026, the dividend rate is $1.72 and the yield is 6.38%. Pfizer has a payout ratio of 125.74% on a trailing twelve-month basis.
When is the next Pfizer dividend payment date?
The next Pfizer (PFE) dividend payment date is unconfirmed.
What is the beta indicator for Pfizer?
Pfizer (PFE) has a beta rating of 0.41. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.